Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma
M Ernst, A Oeser, B Besiroglu… - Cochrane Database …, 2021 - cochranelibrary.com
Background Diffuse large B‐cell lymphoma (DLBCL) is an aggressive cancer of the
lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10 …
lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10 …
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
M Ernst, A Oeser, B Besiroglu… - The Cochrane …, 2021 - europepmc.org
Background Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer of the
lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10 …
lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10 …
[引用][C] Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma
Cochrane Haematology Group, M Ernst… - Cochrane Database …, 1996 - cochranelibrary.com
Background Diffuse large B‐cell lymphoma (DLBCL) is an aggressive cancer of the
lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10 …
lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10 …
Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma
M Ernst, A Oeser, B Besiroglu… - Cochrane Database of …, 2021 - ora.ox.ac.uk
Background Diffuse large B‐cell lymphoma (DLBCL) is an aggressive cancer of the
lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10 …
lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10 …
[HTML][HTML] Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma
M Ernst, A Oeser, B Besiroglu… - The Cochrane …, 2021 - ncbi.nlm.nih.gov
Background Diffuse large B‐cell lymphoma (DLBCL) is an aggressive cancer of the
lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10 …
lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10 …
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma
M Ernst, A Oeser, B Besiroglu… - The Cochrane …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer of the
lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10 …
lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10 …
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma
M Ernst, A Oeser, B Besiroglu… - … Database Syst Rev., 2021 - kups.ub.uni-koeln.de
Background Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer of the
lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10 …
lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10 …
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma
M Ernst, A Oeser, B Besiroglu… - … Database Syst Rev., 2021 - kups.ub.uni-koeln.de
Background Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer of the
lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10 …
lymphatic system. About 30% to 40% of people with DLBCL experience relapse and 10 …